Cookson K. C. Chiu

Cookson K. C. Chiu

Auto-generated profile, based on publicly available information

Cookson K. C. Chiu

Department of Chemistry, University of Warwick, Coventry, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2017 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
PZPingyu Zhang
Pingyu Zhang
CCCookson K. C. Chiu
Cookson K. C. Chiu
HHHuaiyi Huang
Huaiyi Huang
YLYuko P. Y. Lam
Yuko P. Y. Lam
AHAbraha Habtemariam
Abraha Habtemariam
PSPeter J. Sadler
Peter J. Sadler
Strongly luminescent iridium(III) complexes, [Ir(C,N)2(S,S)]+ (1) and [Ir(C,N)2(O,O)] (2), containing C,N (phenylquinoline), O,O (diketonate), or S,S (dithione) chelating ligands, have been characterized by X‐ray crystallography and DFT calculations. Their long phosphorescence lifetimes in living cancer cells give rise to high quantum yields for the generation of 1O2, with large 2‐photon absorption cross‐sections. 2 is nontoxic to cells, but potently cytotoxic to cancer cells upon brief irradiation with low doses of visible light, and potent at sub‐micromolar doses towards 3D multicellular tumor spheroids with 2‐photon red light. Photoactivation causes oxidative damage to specific histidine residues in the key proteins in aldose reductase and heat‐shock protein‐70 within living cancer cells. The oxidative stress induced by iridium photosensitizers during photoactivation can increase the levels of enzymes involved in the glycolytic pathway.

17 May 2017 in Organic & Biomolecular Chemistry
Verified
Journal Article
Open access
PDF file
AGAlessandro Del Grosso
Alessandro Del Grosso
LGLavrentis-Dimitrios Galanopoulos
Lavrentis-Dimitrios Galanopoulos
CCCookson K. C. Chiu
Cookson K. C. Chiu
GCGuy J. Clarkson
Guy J. Clarkson
PCPeter B. O′ Connor
Peter B. O′ Connor
MWMartin Wills
Martin Wills
A series of strained alkynes were prepared from 2,2′-dihydroxy-biaryls. Several were characterised by X-ray crystallography, revealing strained C(sp)–C(sp)–C(sp3) bond angles in the range of 163–167°. Their cycloadditions with azides proceed without a catalyst. Functionalised versions of these reagents have potential applications to materials synthesis and bioconjugations.

19 October 2017 in Angewandte Chemie
Verified
Journal Article
Open access
PDF file
PZPingyu Zhang
Pingyu Zhang
CCCookson K. C. Chiu
Cookson K. C. Chiu
HHHuaiyi Huang
Huaiyi Huang
YLYuko P. Y. Lam
Yuko P. Y. Lam
AHAbraha Habtemariam
Abraha Habtemariam
PSPeter J. Sadler
Peter J. Sadler
Strongly luminescent iridium(III) complexes, [Ir(C,N)2(S,S)]+ (1) and [Ir(C,N)2(O,O)] (2), containing C,N (phenylquinoline), O,O (diketonate), or S,S (dithione) chelating ligands, have been characterized by X‐ray crystallography and DFT calculations. Their long phosphorescence lifetimes in living cancer cells give rise to high quantum yields for the generation of 1O2, with large 2‐photon absorption cross‐sections. 2 is nontoxic to cells, but potently cytotoxic to cancer cells upon brief irradiation with low doses of visible light, and potent at sub‐micromolar doses towards 3D multicellular tumor spheroids with 2‐photon red light. Photoactivation causes oxidative damage to specific histidine residues in the key proteins in aldose reductase and heat‐shock protein‐70 within living cancer cells. The oxidative stress induced by iridium photosensitizers during photoactivation can increase the levels of enzymes involved in the glycolytic pathway.

8 January 2019 in The Analyst
Verified
Journal Article
Closed access
PDF file
CWChristopher A. Wootton
Christopher A. Wootton
AMAdam J. Millett
Adam J. Millett
ALAndrea Lopez
Andrea Lopez
CCCookson K. C. Chiu
Cookson K. C. Chiu
MBMark P. Barrow
Mark P. Barrow
POPeter B. O'COnnor
Peter B. O'COnnor
Organometallic complexes alter peptide MS/MS fragmentation behavior, producing challenging fragmentation channels and electron quenching effects dependent on modification identity.

19 November 2018 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
YLYuko P. Y. Lam
Yuko P. Y. Lam
CWChristopher A. Wootton
Christopher A. Wootton
IHIan Hands-Portman
Ian Hands-Portman
JWJuan Wei
Juan Wei
CCCookson K. C. Chiu
Cookson K. C. Chiu
POPeter B. O’COnnor
Peter B. O’COnnor
Deamidation sites of hIAPP were determined and the amount of fibril formed in mutant hIAPPs was higher than in wild-type hIAPP.

12 May 2025 in Cell Insight
Verified
Journal Article
Open access
HTHuajian Tian
Huajian Tian
GLGuifei Li
Guifei Li
CCCookson K.C. Chiu
Cookson K.C. Chiu
ELE. Li
E. Li
YCYuzong Chen
Yuzong Chen
XKXi Kang
Xi Kang
While immune cell therapies have transformed cancer treatment, achieving comparable success in solid tumors remains a significant challenge compared to hematologic malignancies like non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Over the past four decades, various immunotherapeutic strategies, including tumor vaccines, tumor-infiltrating lymphocyte (TIL) therapies, and T cell receptor (TCR) therapies, have demonstrated clinical efficacy in select solid tumors, suggesting potential advantages over CAR-T and CAR-NK cell therapies in specific contexts. The dynamic nature of the cancer-immunity cycle, characterized by the continuous evolution of tumor-specific neoantigens, enables tumors to evade immune surveillance. This highlights the urgent need for rapid and accurate identification of functional tumor neoantigens to inform the design of personalized tumor vaccines. These vaccines can be based on mRNA, dendritic cells (DCs), or synthetic peptides. In this study, we established a novel platform integrating immunoprecipitation-mass spectrometry (IP-MS) for efficient and direct identification of tumor-specific neoantigen peptides. By combining this approach with our proprietary AI-based prediction algorithm and high-throughput in vitro functional validation, we can generate patient-specific neoantigen candidates within six weeks, accelerating personalized tumor vaccine development.